Neuroblastoma: Current Imaging and Therapeutics

References (98)

1. 1 Amplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage [DOI]
2. 2 Identification of a Chromosome 18q Gene that Is Altered in Colorectal Cancers [DOI]
3. 3 Identification of ALK as a major familial neuroblastoma predisposition gene [DOI]
4. 4 Molecular Biology of Neuroblastoma [DOI]
5. 5 Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose [DOI]
6. 6 Favorable Biology and Outcome of Stage IV-S Neuroblastoma With Supportive Care or Minimal Therapy: A Children’s Cancer Group Study [DOI]
7. 7 Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor‐κB signaling [DOI]
8. 8 Biologic Variables in the Outcome of Stages I and II Neuroblastoma Treated With Surgery as Primary Therapy: A Children’s Cancer Group Study [DOI]
9. 9 Alternative splicing in cancer: Noise, functional, or systematic? [DOI]
10. 10 Phase II Trial of the Anti-GD2Monoclonal Antibody 3F8 and Granulocyte-Macrophage Colony-Stimulating Factor for Neuroblastoma [DOI]
11. 11 Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making [DOI]
12. 12 SPECIAL PATTERN OF WIDESPREAD NEUROBLASTOMA WITH A FAVOURABLE PROGNOSIS [DOI]
13. 13 Biologic Factors Determine Prognosis in Infants With Stage IV Neuroblastoma: A Prospective Children’s Cancer Group Study [DOI]
14. 14 Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. [DOI]
15. 15 Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. [DOI]
16. 16 Extending Positron Emission Tomography Scan Utility to High-Risk Neuroblastoma: Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography as Sole Imaging Modality in Follow-Up of Patients [DOI]
17. 17 Central nervous system metastases in neuroblastoma [DOI]
18. 18 Hyperfractionated Low-Dose Radiotherapy for High-Risk Neuroblastoma After Intensive Chemotherapy and Surgery [DOI]
19. 19 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study. [DOI]
20. 20 Whole-body PET/CT with 11C-meta-hydroxyephedrine in tumors of the sympathetic nervous system: feasibility study and comparison with 123I-MIBG SPECT/CT.
21. 21 Environmental risk factors for brain tumors [DOI]
22. 22 Neuroblastoma Phox2b Variants Stimulate Proliferation and Dedifferentiation of Immature Sympathetic Neurons [DOI]
23. 23 1H MR spectroscopic imaging with short and long echo time to discriminate glycine in glial tumours [DOI]
24. 24 Fractionated low‐dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high‐risk neuroblastoma [DOI]
25. 25 Role of Palliative Radiotherapy in the Management of Metastatic Pediatric Neuroblastoma: A Retrospective Single-Institution Study [DOI]
26. 26 Genetic abnormalities in adolescents and young adults with neuroblastoma: A report from the Italian Neuroblastoma Group [DOI]
27. 27 Evaluating bone marrow metastasis of neuroblastoma with iodine-123-MIBG scintigraphy and MRI.
28. 28 Ganglioneuroma of the adrenal gland: a rare case.
29. 29 Role of charge and hydration in effects of polysialic acid on molecular interactions on and between cell membranes. [DOI]
30. 30 Neuroblastoma [DOI]
31. 31 Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells.
32. 32 Staging of Neuroblastoma at Imaging: Report of the Radiology Diagnostic Oncology Group [DOI]
33. 33 Radionuclide Skeletal Survey in Neuroblastoma [DOI]
34. 34 Follow-up in Neuroblastoma: Comparison of Metaiodobenzylguanidine and a Chimeric Anti-GD2 Antibody for Detection of Tumor Relapse and Therapy Response [DOI]
35. 35 Cell adhesion molecules as targets for therapy of neuroblastoma [DOI]
36. 36 The NF-κB pathway mediates fenretinide-induced apoptosis in SH-SY5Y neuroblastoma cells [DOI]
37. 37 Activity of iodine-123 metaiodobenzylguanidine in childhood neuroblastoma: lack of relation to tumour differentiation in vivo [DOI]
38. 38 Efficacy and safety of [131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma.
39. 39 A prospective comparison between magnetic resonance imaging, meta-iodobenzylguanidine scintigraphy and marrow histology/cytology in neuroblastoma [DOI]
40. 40 Potential role of magnetic resonance spectroscopy in assessment of tumour response in childhood cancer [DOI]
41. 41 Bilateral Adrenal Neuroblastoma is Different [DOI]
42. 42 Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. [DOI]
43. 43 A monoclonal antibody (ERIC-1), raised against retinoblastoma, that recognizes the neural cell adhesion molecule (NCAM) expressed on brain and tumours arising from the neuroectoderm [DOI]
44. 44 Iodine-131 metaiodobenzylguanidine scintigraphy for localization of lesions in children with neuroblastoma: comparison with computed tomography and ultrasonography [DOI]
45. 45 Proton magnetic resonance spectroscopy in neuroblastoma: Current status, prospects and limitations [DOI]
46. 46 Computed tomographic evaluation of Wilms tumor and neuroblastoma [DOI]
47. 47 Risk estimation in localized unresectable single copy MYCN neuroblastoma by the status of chromosomes 1p and 11q [DOI]
48. 48 The role of computed tomography in the management of children with advanced neuroblastoma [DOI]
49. 49 Paratesticular Neuroblastoma [DOI]
50. 50 The Role of 131 Iodine-Metaiodobenzylguanidine Scanning in the Correlative Imaging of Patients With Neuroblastoma [DOI]
51. 51 Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. [DOI]
52. 52 Recent Advances in Neuroblastoma [DOI]
53. 53 The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report [DOI]
54. 54 Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid [DOI]
55. 55 The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report [DOI]
56. 56 ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. [DOI]
57. 57 From the Archives of the AFIP [DOI]
58. 58 International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. [DOI]
59. 59 Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group [DOI]
60. 60 Curcumin (Diferuloylmethane) Down-Regulates Expression of Cell Proliferation and Antiapoptotic and Metastatic Gene Products through Suppression of IκBα Kinase and Akt Activation [DOI]
61. 61 Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial [DOI]
62. 62 Neuroblastoma: a disease requiring a multitude of imaging studies.
63. 63 Neuroblastoma and Other Neuroendocrine Tumors [DOI]
64. 64 Proton MR Spectroscopy of Intracranial Tumours [DOI]
65. 65 P-selectin mediates adhesion of platelets to neuroblastoma and small cell lung cancer. [DOI]
66. 66 Correlation of Early Metastatic Response by123I-Metaiodobenzylguanidine Scintigraphy With Overall Response and Event-Free Survival in Stage IV Neuroblastoma [DOI]
67. 67 Hyperdiploidy Plus Nonamplified MYCN Confers a Favorable Prognosis in Children 12 to 18 Months Old With Disseminated Neuroblastoma: A Pediatric Oncology Group Study [DOI]
68. 68 Favorable Prognosis for Patients 12 to 18 Months of Age With Stage 4 Nonamplified MYCN Neuroblastoma: A Children's Cancer Group Study [DOI]
69. 69 Efficacy of complete resection for high-risk neuroblastoma: a children’s cancer group study [DOI]
70. 70 Integrated Imaging Using MRI and 123| Metaiodobenzylguanidine Scintigraphy to Improve Sensitivity and Specificity in the Diagnosis of Pediatric Neuroblastoma [DOI]
71. 71 Scintigraphic Response by 123I-Metaiodobenzylguanidine Scan Correlates With Event-Free Survival in High-Risk Neuroblastoma [DOI]
72. 72 Evaluation of semi‐quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma [DOI]
73. 73 PET hydroxyephedrine imaging of neuroblastoma.
74. 74 Linear discriminant analysis of brain tumour 1H MR spectra: a comparison of classification using whole spectra versus metabolite quantification [DOI]
75. 75 Non‐invasive detection of glycine as a biomarker of malignancy in childhood brain tumours using in‐vivo1H MRS at 1.5 Tesla confirmed by ex‐vivo high‐resolution magic‐angle spinning NMR [DOI]
76. 76 New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status.
77. 77 Familial neuroblastoma. Case reports, literature review, and etiologic considerations [DOI]
78. 78 Classification of biopsy-confirmed brain tumors using single-voxel MR spectroscopy.
79. 79 Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. [DOI]
80. 80 Imaging the adrenal medulla with an I-131-labeled antiadrenergic agent.
81. 81 Metastatic neuroblastoma in children older than one year: Prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system [DOI]
82. 82 Treatment of Neuroblastoma Patients with Antiganglioside GD2 Antibody plus Interleukin-2 Induces Antibody-Dependent Cellular Cytotoxicity Against Neuroblastoma Detected In Vitro [DOI]
83. 83 Clinical Impact and Prognostic Value of Metaiodobenzylguanidine Imaging in Children With Metastatic Neuroblastoma [DOI]
84. 84 Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors.
85. 85 N-Myc overexpression leads to decreased β1 integrin expression and increased apoptosis in human neuroblastoma cells [DOI]
86. 86 Curcumin induces apoptosis in human neuroblastoma cells via inhibition of NFkappaB.
87. 87 Concomitant down-regulation of expression of integrin subunits by N-myc in human neuroblastoma cells: differential regulation of α2, α3 and β1 [DOI]
88. 88 Age at Diagnosis and Prognosis in Children With Neuroblastoma [DOI]
89. 89 Predicting Resistance or Response to Chemotherapy by Proton Magnetic Resonance Spectroscopy in Neuroblastoma [DOI]
90. 90 MIBG and somatostatin receptor analogs in children: current concepts on diagnostic and therapeutic use.
91. 91 Polysialylated neural cell adhesion molecule as a marker for differential diagnosis in pediatric tumors [DOI]
92. 92 Radionuclide Bone Scan in Neuroblastoma [DOI]
93. 93 Primary neuroblastoma uptake of 99mtechnetium methylene diphosphonate. [DOI]
94. 94 Prolonged survival of a patient with disseminated neuroblastoma [DOI]
95. 95 Neonatal neuroblastoma presenting with respiratory distress [DOI]
96. 96 Abdominal neuroblastoma: magnetic resonance imaging and tissue characterization. [DOI]
97. 97 Aggressive neuroblastoma simulating Wilms tumor. [DOI]
98. 98 Expression of PSA-N-CAM in human neuroblastoma cells induced to neuronal differentiation by retinoic acid.

Cited by 0

No indexed citations yet.

Related research

• Effects of Breast Cancer Stem Cell Extract Primed Dendritic Cell Transplantation on Breast Cancer Tumor Murine Models — shares topic coverage
• Accessibility and Inclusivity of Chimeric Antigen Receptor T-cell Immunotherapy in Treating Hematological Malignancies — shares topic coverage
• The Role of Invariant Natural Killer T Cells in Cancer — shares topic coverage
• The Effect of Immunotherapy on Some Immunological Parameters of Airway Allergic Patients in Province of Babylon/Iraq — shares topic coverage
• A Comprehensive Review on Cancer Immunotherapy in Veterinary Medicine — shares topic coverage